CliffBio
small molecule

TYZAVAN

VANCOMYCIN HYDROCHLORIDE

Loss of exclusivityNovember 2035latest FDA-listed patent expiry
CompanyHikma →View the full company profile on CliffBio

Drug detail

Brand nameTYZAVAN
Active ingredientVANCOMYCIN HYDROCHLORIDE
StrengthEQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2019
Marketing statusRX

Listed patents

PatentExpiresType
10039804November 2035product
10188697November 2035product
11517609November 2035use U-282
11628200November 2035product
12161690November 2035product
10849956November 2035product

More from Hikma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TYZAVAN patent cliff — loss of exclusivity November 2035 | CliffBio